December 2, 2022
Loading...
You are here:  Home  >  Health Care & Life Science  >  Current Article

Amgen gets FDA approval to change Kyprolis label

IN THIS ARTICLE

Biotech giant Amgen announced Jan. 17 that the U.S. Food and Drug Administration approved changes to the label of its multiple myeloma drug Kyprolis. Data from a Phase 3 study showed that overall survival increased by 7.6 months in patients using Kyprolis alongside dexamethasone, and that the risk of death decreased 21 percent. "Overall survival…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.